Sanofi (SNY) Announces Earnings Results

Sanofi (NYSE:SNY) posted its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.74, Morningstar.com reports. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company had revenue of $8.66 billion for the quarter, compared to analysts’ expectations of $8.71 billion. Sanofi’s quarterly revenue was down 2.3% on a year-over-year basis.

Shares of Sanofi (NYSE:SNY) opened at 48.19 on Friday. The company has a market cap of $121.03 billion, a P/E ratio of 11.43 and a beta of 0.88. The firm has a 50-day moving average price of $47.84 and a 200-day moving average price of $46.41. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24.

TRADEMARK VIOLATION NOTICE: “Sanofi (SNY) Announces Earnings Results” was first published by BNB Daily and is the property of of BNB Daily. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/19/sanofi-sny-announces-earnings-results-updated-updated.html.

SNY has been the topic of a number of research analyst reports. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a report on Monday, April 24th. BidaskClub raised Sanofi from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Argus boosted their price target on Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, June 9th. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a report on Friday, June 2nd. Finally, Berenberg Bank downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $54.00.

A number of institutional investors have recently made changes to their positions in the company. BLB&B Advisors LLC bought a new position in shares of Sanofi during the first quarter worth approximately $202,000. Atria Investments LLC increased its position in shares of Sanofi by 8.9% in the first quarter. Atria Investments LLC now owns 7,386 shares of the company’s stock worth $334,000 after buying an additional 602 shares during the last quarter. TNB Financial bought a new position in shares of Sanofi during the first quarter worth approximately $1,329,000. Capstone Asset Management Co. increased its position in shares of Sanofi by 6.0% in the first quarter. Capstone Asset Management Co. now owns 82,197 shares of the company’s stock worth $3,719,000 after buying an additional 4,635 shares during the last quarter. Finally, Gradient Investments LLC increased its position in shares of Sanofi by 15,470.7% in the first quarter. Gradient Investments LLC now owns 6,384 shares of the company’s stock worth $289,000 after buying an additional 6,343 shares during the last quarter. Hedge funds and other institutional investors own 9.90% of the company’s stock.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Earnings History for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply